Pharmaceutical compositions comprising mixed antibodies for Anti-CTLA4 and Anti-PD1
Patent Information
- Application Number
- CN202380031424.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-13
- Filing Date
- 2023-04-12
- Publication Date
- 2024-11-12
AI Technical Summary
The existing anti-PD-1 monoclonal antibody treatment regimen has poor efficacy in patients with microsatellite stable colorectal cancer, and there is a lack of dual-target immunotherapy drugs to fill the clinical gap, making it difficult to treat the entire population or other biomarker-enriched populations. need.
Developing a hybrid antibody pharmaceutical composition containing an effective amount of anti-CTLA4 and anti-PD1, combined with a pharmaceutically acceptable carrier and other therapeutic agents such as chemotherapeutic drugs and anti-angiogenic agents, for the treatment of unresectable or metastatic colorectal cancer , especially mismatch repair protein deficient or highly microsatellite unstable and microsatellite stable cancers.
This mixed antibody alone or in combination with bevacizumab shows promising therapeutic effects in advanced colorectal cancer and is safe. It fills the clinical gap in dual-immune combination therapy and improves the effectiveness and safety of treatment. .
Abstract
Description
Pharmaceutical composition comprising mixed antibodies of anti-CTLA4 and anti-PD1 and therapeutic use thereof Technical Field
[0001] The present disclosure relates to the treatment of cancer, particularly colorectal cancer, including immunotherapy and combination therapy. More specifically, the present disclosure relates to the use of a pharmaceutical composition comprising a mixed antibody of anti-CTLA4 and anti-PD1 for the treatment of colorectal cancer. Background Art
[0002] The 2020 edition of the GLOBOCAN statistical report shows that in 2020, there were approximately 19.3 million new cases of cancer and nearly 10 million cancer deaths worldwide. Among them, colorectal cancer (CRC) accounted for approximately 10.0% of new cases, ranking third; and deaths accounted for approximately 9.4%, ranking second. In February 2022, the latest cancer statistics from the National Cancer Center of China showed that the incidence of colorectal cancer in China ranked third, with 408,000 cases; and the mortality rate ranked fourth, with 195,600 deaths. The incidence and mortality rates of colorectal cancer have maintained an upward trend, and it is a major disease type that threatens global human health. Because CRC has no obvious early symptoms, approximately 20% of patients have already metastasized or progressed to the late stage when diagnosed, and more than 50% of early-stage CRC patients will eventually relapse or metastasize.
[0003] Treatment for CRC is primarily surgical, combined with endoscopic therapy, chemotherapy, and radiotherapy. Palliative treatment for advanced colorectal cancer is stratified based on molecular marker testing results. dMMR (mismatch repair protein deficiency) / MSI-H (microsatellite instability-high) CRC accounts for approximately 12% to 15% of the CRC population, and approximately 5% of advanced cases. KRAS and NRAS are GTPase proteins encoded by genes belonging to the RAS family. They participate in epidermal growth factor receptor signaling, regulating cell growth, differentiation, proliferation, and survival. KRAS point mutations occur in 40% to 50% of colorectal cancer patients, while NRAS point mutations occur in 3.8% of colorectal cancer patients. Furthermore, the BRAF gene, a member of the RAF proto-oncogene family, lies downstream of the RAS gene and is a key player in the RAS-RAF-MEK kinase pathway. The BRAF mutation rate in Asian colorectal cancer patients is 5.4% to 6.7%. Among patients with metastatic colorectal cancer who harbor a BRAF mutation, 90% harbor the BRAF V600E mutation.
[0004] For patients with dMMR / MSI-H CRC, immune checkpoint inhibitors (ICIs) have become the standard of care for both first-line and later-line palliative treatment, and have demonstrated superior efficacy compared to chemotherapy in the perioperative neoadjuvant setting of CRC. Currently, a variety of anti-PD-1 / PD-L1 monoclonal antibodies have been approved worldwide for second-line and later-line treatment of dMMR / MSI-H metastatic colorectal cancer (mCRC), including pembrolizumab, nivolumab, envobalizumab, tislelizumab, serotonin, and putalizumab. Based on the KEYNOTE-177 study, pembrolizumab has been approved for first-line treatment of dMMR / MSI-H mCRC. However, no anti-PD-1 / PD-L1 monoclonal antibody combined with an anti-CTLA-4 monoclonal antibody has been approved for this indication.
[0005] For patients with MSS (microsatellite stable) CRC, ICIs have been ineffective as a second-line systemic treatment. Anti-PD-1 monoclonal antibodies combined with standard therapy have shown some efficacy as first-line treatment for metastatic CRC, but further improvement is needed. In the first-line treatment of metastatic CRC, RAS / RAF gene mutations indicate a poorer prognosis with anti-EGFR targeted therapy compared to anti-VEGF monoclonal antibodies (such as bevacizumab). However, this prognostic indicator has not yet been confirmed in immunotherapy.
[0006] ZPML265 is a hybrid antibody drug formulation composed of a recombinant humanized IgG1 monoclonal antibody targeting human CTLA4 and a recombinant humanized IgG4 monoclonal antibody targeting human PD1. These two different antibodies are produced by a single host cell. This hybrid antibody can simultaneously and specifically bind to CTLA4 and PD1, thereby blocking the immune checkpoint signaling pathways between CTLA-4 and B7-1 / B7-2, and between PD-1 and PD-L1. This relieves the inhibitory effects of these two pathways on T lymphocytes, restoring their functional activity and anti-tumor immune responses, thereby enabling the body to fight and kill tumors. Unlike the combination of nivolumab and ipilimumab, ZPML265 allows for continuous administration of the CTLA-4 monoclonal antibody during the combination therapy, further enhancing its therapeutic efficacy.
[0007] However, dMMR / MSI-H CRCs account for a relatively small proportion, and the vast majority of CRCs respond poorly to immune checkpoint inhibitors. Currently, no immunotherapy products have been approved for the entire colorectal cancer population or other biomarker-enriched populations, creating an unmet clinical need that urgently needs to be addressed in this field. Therefore, immunotherapy and / or combination therapy options are of great significance as potential treatment options.
[0008] SUMMARY OF THE INVENTION
[0009] The technical problem to be solved by the present disclosure is to provide an immunotherapy to fill the clinical gap in the international lack of dual-target immune (dual-immune) therapeutic drugs for colorectal cancer, thereby solving such unmet clinical needs.
[0010] The present disclosure provides a pharmaceutical composition for treating colorectal cancer, comprising an effective amount of a mixed antibody of anti-CTLA4 and anti-PD1.
[0011] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0012] In some embodiments, the pharmaceutical composition further comprises an additional therapeutic agent, including but not limited to chemotherapeutic agents (chemotherapeutic drugs), cytotoxic agents, radiotherapeutic agents, cancer vaccines, tumor reducing agents, targeted anti-cancer agents, anti-angiogenic agents, biological response modifiers, cytokines, hormones, anti-metastatic agents, and immunotherapeutic agents.
[0013] In some embodiments, the additional therapeutic agents are chemotherapeutic agents and anti-angiogenic agents, preferably chemotherapeutic agents are oxaliplatin and capecitabine, and preferably anti-angiogenic agents are bevacizumab.
[0014] In some embodiments, the colorectal cancer described in the present disclosure is unresectable or metastatic colorectal cancer.
[0015] Preferably, the unresectable or metastatic colorectal cancer is mismatch repair protein-deficient (dMMR) or highly microsatellite instability (MSI-H) colorectal cancer; another preferred embodiment is that the unresectable or metastatic colorectal cancer is microsatellite stable (MSS) colorectal cancer.
[0016] Therefore, the present disclosure also preferably provides a pharmaceutical composition for treating unresectable or metastatic mismatch repair protein-deficient (dMMR) or high microsatellite instability (MSI-H) colorectal cancer, which contains an effective amount of mixed antibodies against CTLA4 and anti-PD1.
[0017] At the same time, the present disclosure also preferably provides a pharmaceutical composition for treating unresectable or metastatic microsatellite stable (MSS) colorectal cancer, which contains an effective amount of a mixed antibody of anti-CTLA4 and anti-PD1, a chemotherapy drug and an anti-angiogenic agent.
[0018] More preferably, unresectable or metastatic microsatellite stable (MSS) colorectal cancer is a case where the KRAS, NRAS and BRAF genes are all wild-type; alternatively, unresectable or metastatic microsatellite stable (MSS) colorectal cancer may also be a case where any one of the KRAS, NRAS and BRAF genes is mutant.
[0019] In some embodiments, the hybrid antibody is produced by a single host cell that contains nucleic acids encoding two different antibodies, anti-CTLA4 and anti-PD1, wherein the sequences of the anti-CTLA4 antibody heavy chain HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 1, 2, and 3, respectively, the sequences of the anti-CTLA4 antibody light chain LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 4, 5, and 6, respectively, the sequences of the anti-PD1 antibody heavy chain HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 9, 10, and 11, respectively, and the sequences of the anti-PD1 antibody light chain LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 12, 13, and 14, respectively.
[0020] In some embodiments, the heavy chain variable region sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 7, the light chain variable region sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 8, the heavy chain variable region sequence of the anti-PD1 antibody is shown in SEQ ID NO: 15, and the light chain variable region sequence of the anti-PD1 antibody is shown in SEQ ID NO: 16.
[0021] In some embodiments, the heavy chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 17, the light chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 18, the heavy chain sequence of the anti-PD1 antibody is shown in SEQ ID NO: 19, and the light chain sequence of the anti-PD1 antibody is shown in SEQ ID NO: 20.
[0022] The dosage of the mixed antibody is 5 mg / kg, administered once every three weeks by intravenous infusion on the first day, and a treatment cycle of 21 days.
[0023] The dosage of oxaliplatin injection is 130 mg / m 2 , administered by intravenous infusion on the first day, with a treatment cycle of 21 days; the dosage of the chemotherapy drug capecitabine tablets was 1000 mg / m 2 , orally, twice a day, starting on the first day of every 3 weeks, stopping for 1 week after every 2 weeks of medication, and every 3 weeks (21 days) as a treatment cycle; the dosage of bevacizumab injection is 7.5 mg / kg, intravenous infusion, once on the first day of every 3 weeks, and every 3 weeks as a treatment cycle.
[0024] Among them, oxaliplatin is used for up to 8 treatment cycles, and capecitabine tablets are used for up to 2 years.
[0025] Furthermore, the present disclosure provides a method for treating colorectal cancer, comprising administering to a subject a pharmaceutical composition, wherein the pharmaceutical composition is the aforementioned mixed antibody comprising an effective amount of anti-CTLA4 and anti-PD1.
[0026] The present disclosure also preferably provides a method for treating unresectable or metastatic mismatch repair protein-deficient (dMMR) or high microsatellite instability (MSI-H) colorectal cancer, the method comprising administering to a subject a pharmaceutical composition, which is the aforementioned mixed antibody comprising an effective amount of anti-CTLA4 and anti-PD1.
[0027] The present disclosure also preferably provides a method for treating unresectable or metastatic microsatellite stable (MSS) colorectal cancer, the method comprising administering to a subject a pharmaceutical composition, the pharmaceutical composition being the aforementioned mixed antibody comprising an effective amount of anti-CTLA4 and anti-PD1, a chemotherapeutic drug, and an anti-angiogenic agent.
[0028] The results of a phase I clinical study of the hybrid antibody disclosed herein as a single drug showed that the 27 patients with advanced CRC enrolled had a certain therapeutic effect and good safety. At the same time, the clinical study based on the hybrid antibody disclosed herein combined with bevacizumab that has been carried out also showed that immune checkpoint inhibitors combined with anti-angiogenic drugs can play a synergistic anti-tumor effect in advanced colorectal cancer. Therefore, the hybrid antibody monotherapy or the combination of hybrid antibodies, chemotherapy drugs and bevacizumab provided by the present disclosure is expected to have controllable safety and good patient compliance for the medical treatment of advanced colorectal cancer, and can largely fill the gap in the approval of dual-immune combination therapy drugs, and solve the urgent unmet clinical needs. DETAILED DESCRIPTION
[0029] the term
[0030] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0031] Before describing the present disclosure in detail below, it should be understood that the present disclosure is not limited to the specific methodologies, protocols and reagents described herein, as these may vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of the present disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present disclosure belongs.
[0032] Certain embodiments disclosed herein include numerical ranges, and certain aspects of the present disclosure may be described in terms of ranges. Unless otherwise stated, it should be understood that numerical ranges or descriptions in terms of ranges are intended for simplicity and convenience and should not be considered as strict limitations on the scope of the present disclosure. Therefore, descriptions in terms of ranges should be considered to specifically disclose all possible subranges and all possible specific numerical points within the range, as these subranges and numerical points have been clearly stated herein. Regardless of the width of the numerical value, the above principles apply equally. When describing in terms of ranges, the range includes the endpoints of the range.
[0033] When referring to a measurable value such as an amount, a temporal duration, etc., the term "about" is meant to include variations of ±20%, or in some cases ±10%, or in some cases ±5%, or in some cases ±1%, or in some cases ±0.1% of the specified value.
[0034] As used herein, the three-letter and one-letter codes for amino acids are as described in J. Biol. Chem, 243, p3558 (1968).
[0035] The term "antibody" as used herein typically refers to a Y-shaped tetrameric protein comprising two heavy (H) polypeptide chains (HC) and two light (L) polypeptide chains (LC) held together by covalent disulfide bonds and non-covalent interactions. Natural IgG antibodies have this structure. Each light chain consists of a variable domain (VL) and a constant domain (CL). Each heavy chain comprises a variable domain (VH) and a constant region (CH).
[0036] Five major classes of antibodies are known in the art: IgA, IgD, IgE, IgG, and IgM. The corresponding heavy chain constant domains are designated α, δ, ε, γ, and μ, respectively. IgG and IgA can be further divided into different subclasses, e.g., IgG can be divided into IgG1, IgG2, IgG3, and IgG4, and IgA can be divided into IgA1 and IgA2. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, designated κ and λ, based on the amino acid sequence of their constant domains.
[0037] The term "variable region" or "variable domain" shows significant changes in the amino acid composition from one antibody to another, and is primarily responsible for antigen recognition and binding. The variable region of each light chain / heavy chain pair forms an antibody binding site, so that a complete IgG antibody has two binding sites (i.e., it is bivalent). The variable region (VH) of the heavy chain and the variable region (VL) of the light chain each contain three regions with extreme variability, referred to as hypervariable regions (HVRs), or more generally, referred to as complementary determining regions (CDRs). VH and VL each have four skeleton regions FR (or framework regions), represented by FR1, FR2, FR3, and FR4, respectively. Therefore, CDR and FR sequences typically appear in the following sequence of a heavy chain variable domain (VH) (or light chain variable domain (VL)): FR1-HCDR1 (LCDR1)-FR2-HCDR2 (LCDR2)-FR3-HCDR3 (LCDR3)-FR4.
[0038] The types of "antibodies" in a broad sense may include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies and primatized antibodies, CDR-grafted antibodies, human antibodies (including recombinantly produced human antibodies), recombinantly produced antibodies, intracellular antibodies, multispecific antibodies, bispecific antibodies, single-chain antibodies, monovalent antibodies, multivalent antibodies, single-domain antibodies, nanobodies, synthetic antibodies (including muteins and variants thereof), etc.
[0039] The term "monoclonal antibody" (or "mAb") refers to a substantially homogeneous antibody produced by a single cell clone that is directed against a specific antigenic epitope. Monoclonal antibodies can be prepared using a variety of techniques known in the art, including hybridoma technology, recombinant technology, phage display technology, transgenic animals, synthetic technology, or a combination of these techniques.
[0040] It should be noted that the division of the CDRs and FRs in the antibody variable regions of the present disclosure is determined according to the Kabat definition. Other naming and numbering systems, such as Chothia, IMGT, or AHo, are also known to those skilled in the art. Therefore, humanized antibodies containing one or more CDRs derived from any naming system based on the antibody sequences of the present disclosure are clearly within the scope of the present disclosure.
[0041] The term "antigen" refers to a substance that is recognized and specifically bound by an antibody or antibody binding fragment. In a broad sense, an antigen can include any immunogenic fragment or determinant of a selected target, including a single epitope, multiple epitopes, a single domain, multiple domains, or a complete extracellular domain (ECD) or protein.
[0042] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear, cyclic, or branched, it may contain modified amino acids, particularly conservatively modified amino acids, and it may be interrupted by non-amino acids. The term also includes amino acid polymers that have been modified, for example, by glycosylation, lipidation, acetylation, phosphorylation, methylation, and the like.
[0043] As used herein, the term "hybrid antibody" refers to an antibody containing a limited number of primary antibody species, optionally no more than two, three, four, five, six, seven, eight, nine, or ten, produced from host cells (optionally cells from a single host cell line) that have been transfected with DNA encoding at least two different antibodies (optionally full-length primate IgG antibodies) with different binding specificities. In some embodiments, DNA encoding at least two different heavy chains (HCs) and at least two different light chains (LCs) can be introduced into the same host cell. For example, a host cell can be transfected with DNA encoding at least two but no more than four different antibodies with different binding specificities. In some embodiments, the sequences of all transfected DNA encoding HCs and LCs can be mutated to alter the amino acid sequence of the antibody, thereby disfavoring non-homologous HC / LC pairing and strongly favoring homologous HC / LC pairing. In the case of introducing two different HCs into the host cell, one or both of the two different HCs can be optionally altered to disfavor heterodimer formation. In some embodiments, only one heavy chain is altered to prevent heterodimer formation. In some embodiments, when DNA encoding only two different antibodies is introduced into a host cell, only one of the antibodies encoded by the DNA comprises one or more partner-directed changes that favor cognate HC / LC pairing, while the other antibody does not comprise such changes. In some embodiments, the host cell produces only two major antibody species, wherein each HC predominantly pairs with its cognate LC, and most antibodies are tetramers containing two heavy chains having the same amino acid sequence and two light chains having the same amino acid sequence (see PCT / US2017 / 030676).
[0044] The term "pharmaceutical composition" refers to a formulation or combination of formulations containing one, two, or more active ingredients, which allows the active ingredients contained therein to exist in a biologically effective form and does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered. When a "pharmaceutical composition" is present as a combination of separate formulations containing two or more different active ingredients, they can be administered simultaneously, sequentially, separately, or at intervals, with the goal of exerting the biological activities of the multiple active ingredients for combined treatment of a disease.
[0045] The term "pharmaceutical carrier" or "pharmaceutically acceptable carrier" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which the therapeutic agent is administered.
[0046] The term "effective amount" refers to a dose of a pharmaceutical formulation comprising an active ingredient of the present disclosure that produces the desired effect in a treated patient after administration to the patient in a single or multiple doses. The effective amount can be readily determined by the attending physician, who is skilled in the art, by considering a variety of factors such as ethnic differences; weight, age, and health status; the specific disease involved; the severity of the disease; the response of the individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosing regimen; and the use of any concomitant therapy.
[0047] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
[0048] The term "transfection" as used herein refers to the introduction of exogenous nucleic acid into eukaryotic cells. Transfection can be achieved by various means known in the art, including electroporation, microinjection, liposome fusion, etc.
[0049] The terms "nucleic acid molecule encoding," "coding DNA sequence," and "coding DNA" refer to the order of deoxyribonucleotides along a deoxyribonucleic acid chain. The order of these deoxyribonucleotides determines the order of amino acids along a polypeptide (protein) chain. Thus, a nucleic acid sequence encodes an amino acid sequence.
[0050] Methods for producing and purifying antibodies and antigen-binding fragments are well known and can be found in the prior art, such as the Cold Spring Harbor Manual of Antibody Laboratory Techniques, Chapters 5-8 and 15. The engineered antibodies or antigen-binding fragments thereof disclosed herein can be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into expression vectors. The recombinant immunoglobulin expression vector can be stably transfected into CHO cells. Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are expanded in serum-free culture medium in a bioreactor to produce antibodies. The culture fluid that secretes the antibodies can be purified and collected using conventional techniques. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange.
[0051] As used herein, the term "individual" or "subject" refers to any animal, such as a mammal or marsupial. Individuals of the present disclosure include, but are not limited to, humans, non-human primates (e.g., cynomolgus or rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cattle, sheep, rats, and any type of poultry.
[0052] As used herein, the terms "disease," "condition," or "disorder" refer to any change or disorder that damages or interferes with the normal function of a cell, tissue, or organ. For example, "disease" includes, but is not limited to, tumors, pathogen infection, autoimmune diseases, T-cell dysfunction, or immune tolerance deficiency (e.g., transplant rejection).
[0053] As used herein, the term "tumor" refers to a disease characterized by the pathological proliferation of cells or tissues, and their subsequent migration or invasion of other tissues or organs. Tumor growth is typically uncontrolled and progressive, without inducing or inhibiting normal cell proliferation. Tumor includes "cancer" and refers broadly to all malignant tumors.
[0054] As used herein, the term "treatment" refers to clinical intervention aimed at altering the course of a disease in an individual or cell, and can be either preventative or interventional in the clinical pathological process. Therapeutic effects include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, slowing the progression of a disease, improving or relieving the condition, and alleviating or improving the prognosis.
[0055] The term "combination" as used herein refers to a treatment regimen that provides at least two or more different therapies to achieve a specified therapeutic effect. The therapies can be physical, such as radiotherapy, or chemical, such as administering a drug to a subject, and the drug also includes a combination drug. "Combination drug" refers to a combination of two or more pharmaceutical preparations, each of which has an active ingredient, that need to be used in combination when administered to a subject. The active ingredients can be mixed together to form a single dosing unit, or they can be independently administered as dosing units and used separately; when administered, different pharmaceutical preparations can be administered essentially synchronously, simultaneously or sequentially.
[0056] Overall survival (OS) is defined as the time from the start of study treatment to death from any cause. Patients who were still in follow-up at the cut-off date were censored based on the analysis cut-off date. Subjects lost to follow-up were censored based on the date of last contact.
[0057] Progression-free survival (PFS) refers to the time from the start of study treatment to the first imaging assessment of disease progression or death from any cause (whichever occurs first).
[0058] The objective response rate (ORR) was defined as the best confirmed ORR during the study period, including both complete responses (CR) and partial responses (PR). According to RECIST v1.1, additional imaging was required to confirm the first occurrence of a PR or CR at ≥4 weeks.
[0059] Disease control rate (DCR) refers to the percentage of cases with the best efficacy evaluation as "CR+PR+SD".
[0060] Complete remission (CR): All target lesions disappear and the short diameter of all pathological lymph nodes (including target nodules and non-target nodules) must be reduced to <10mm.
[0061] Partial response (PR): The sum of the target lesion diameters decreased by at least 30% compared with the baseline level.
[0062] Disease progression (PD): The minimum value of the sum of all target lesion diameters measured during the entire experimental study is used as a reference, and the relative increase in the diameter sum is at least 20% (if the baseline measurement value is the minimum, the baseline value is used as a reference); in addition, the absolute value of the diameter sum must increase by at least 5 mm (the appearance of one or more new lesions is also considered as disease progression).
[0063] Stable disease (SD): The target lesion has not decreased to the level of PR, nor increased to the level of PD, but is somewhere in between. The minimum sum of the diameters can be used as a reference for research.
[0064] Duration of response (DOR) was defined as the time from the first tumor assessment as CR or PR (whichever was recorded first) to the first assessment as PD or death.
[0065] Treatment-emergent adverse events (TEAEs) refer to adverse events that occur during treatment.
[0066] Treatment-related adverse events (TRAEs) are adverse events related to study drugs that occur during treatment.
[0067] A serious adverse event (SAE) refers to an adverse medical event such as death, life-threatening, permanent or severe disability or loss of function, the need for hospitalization or prolonged hospitalization, and congenital anomalies or birth defects that occurs in a subject after receiving an investigational drug.
[0068] Example
[0069] The present disclosure is further described below with reference to specific examples. It should be understood that these examples are only used to illustrate the present disclosure and are not intended to limit the scope of the present disclosure.
[0070] Example 1 Obtaining the hybrid antibody ZPML265
[0071] A hybrid antibody produced by a single host cell line was prepared (see PCT / US2017 / 030676). The hybrid antibody contains two active ingredients: a recombinant humanized IgG1 monoclonal antibody targeting human CTLA4 and a recombinant humanized IgG4 monoclonal antibody targeting human PD1. The hybrid antibody can specifically bind to both human CTLA4 and PD1. After the two antibodies are simultaneously expressed in a single host cell line, they are collected, purified, and combined with a pharmaceutically acceptable carrier to form a single hybrid antibody pharmaceutical preparation, ZPML265. The amino acid sequences of the anti-CTLA4 antibody and the anti-PD1 antibody are shown in Table 1 below.
[0072] Table 1 Amino acid sequences of the components of the mixed antibody ZPML265
[0073] Example 2 Efficacy and safety of ZPML265 monotherapy in the treatment of advanced colorectal cancer
[0074] Dosage:
[0075] In a Phase I clinical study conducted in China, 27 patients with pathologically confirmed metastatic or recurrent colorectal cancer were enrolled, including 26 patients with colorectal adenocarcinoma. The patients were aged 18 years or older, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had an expected survival of 3 months or more. The functional level of vital organs before the first use of the investigational drug was:
[0076] 1) Absolute neutrophil count ≥1.5×10 9 / L;
[0077] 2) Platelets ≥75×10 9 / L;
[0078] 3) Hemoglobin ≥90 g / L;
[0079] 4) serum albumin ≥30 g / L;
[0080] 5) Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ 2.5 × upper limit of normal reference value (ULN) (for patients with liver cancer or liver metastasis, ≤ 5 × ULN is allowed);
[0081] 6) Total bilirubin ≤1.5×ULN (≤3×ULN is allowed for patients with Gilbert syndrome);
[0082] 7) International normalized ratio (INR) ≤ 1.5; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
[0083] 8) Serum creatinine ≤ 1.5 × ULN. If the subject's creatinine level is > 1.5 × ULN, creatinine clearance (CrCl) ≥ 50 mL / min (calculated according to the Cockcroft-Gault formula);
[0084] 9) Left ventricular ejection fraction (LVEF)>50%.
[0085] Dosage regimen: ZPML265 is administered at a dose of 5 mg / kg via intravenous infusion once every three weeks.
[0086] Effectiveness Results:
[0087] In the 27 subjects treated with ZPML265 monotherapy for CRC, the confirmed ORR was 7.4% (95% CI: 0.910, 24.290) and the DCR was 25.9% (95% CI: 11.114, 46.285), including 2 PRs and 5 SDs. ZPML265 monotherapy has demonstrated limited efficacy in advanced CRC.
[0088] Safety results:
[0089] Safety data were compiled from 609 subjects treated with ZPML265. As of May 31, 2022, 546 (89.7%) patients experienced TEAEs and 451 (74.1%) patients experienced TEAEs related to ZPML265. Grade ≥3 TEAEs and SAEs were reported in 187 (30.7%) and 156 (25.6%) patients, respectively, and Grade ≥3 TEAEs related to ZPML265 and SAEs related to ZPML265 were reported in 102 (16.7%) and 75 (12.3%) patients, respectively.
[0090] TRAEs with an incidence of ≥10% included rash (17.6%), pruritus (12.3%), hypothyroidism (11.3%), hyperthyroidism (10.3%), anemia (10%), and increased aspartate aminotransferase (10%). Grade ≥3 TRAEs occurred in 16.7% of patients, and TRAEs with an incidence of ≥1% included anemia (2.3%), increased aspartate aminotransferase (1.1%), and increased alanine aminotransferase (1.0%).
[0091] In comparison with ZPML265 monotherapy, another meta-analysis that summarized 2,664 cases of nivolumab combined with ipilimumab showed that the overall incidence of treatment-related serious adverse events was 29.6%, and the incidence of grade ≥3 TRAEs was 39.9%, which were higher than the relevant data of ZPML265 monotherapy.
[0092] Existing data show that the treatment safety is acceptable and no new safety signals have been found compared with other immunotherapy drugs.
[0093] in conclusion:
[0094] Overall, ZPML265 monotherapy for advanced CRC showed promising therapeutic effects. In terms of safety, the incidence of TRAEs was similar to that of anti-PD-(L)1 monotherapy and lower than that of the dual-drug combination therapy of Nivolumab + Ipilimumab. That is, while ensuring drug efficacy, its safety is better than existing clinical regimens in existing technologies.
[0095] Example 3 A Phase II clinical study evaluating ZPML265 alone or in combination with bevacizumab and XELOX as first-line treatment for unresectable locally advanced or metastatic CRC
[0096] In a Phase II clinical study of ZPML265 monotherapy combined with bevacizumab and XELOX regimen as the first-line treatment for unresectable locally advanced or metastatic CRC, patients with unresectable locally advanced or metastatic colorectal adenocarcinoma confirmed by histological examination were enrolled and divided into two cohorts: Cohort 1 enrolled the MSI-H population, and Cohort 2 enrolled the low microsatellite instability (MSI-L) or MSS and RAS, BRAF wild-type population. Patients were ≥18 years old, regardless of gender. Eastern Cooperative Oncology Group (ECOG) physical status score was 0-1. Expected survival was ≥3 months. The functional level of important organs before the first use of the trial drug must meet the following requirements:
[0097] 1) Neutrophil count (ANC) ≥ 1.5 × 10 9 / L;
[0098] 2) Platelet count (PLT) ≥ 90 × 10 9 / L;
[0099] 3) Hemoglobin (Hb) ≥ 90 g / L;
[0100] 4) Albumin (ALB) ≥ 30 g / L;
[0101] 5) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal range (ULN). For subjects with liver metastasis, AST and ALT are required to be ≤ 5 × ULN;
[0102] 6) Serum total bilirubin (TBIL) ≤ 1.5 × ULN (for subjects with Gilbert syndrome, TBIL is required to be < 3 × ULN);
[0103] 7) serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 50 mL / min (using the standard Cockcroft-Gault formula);
[0104] 8) Left ventricular ejection fraction (LVEF)>50%;
[0105] 9) Urine protein qualitative ≤1+ (if ≥2+, a 24-hour urine protein test is required, and if the result is <1g, inclusion is allowed);
[0106] 10) Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN, international normalized ratio (INR) ≤ 1.5, prothrombin time (PT) ≤ 1.5 × ULN.
[0107] Dosage regimen:
[0108] Queue 1:
[0109] The dose of ZPML265 is 5 mg / kg, administered by intravenous infusion, once on the first day every 3 weeks, and every 3 weeks is a treatment cycle;
[0110] Queue 2:
[0111] The dose of ZPML265 is 5 mg / kg, administered by intravenous infusion, once on the first day every 3 weeks, and every 3 weeks is a treatment cycle;
[0112] The dosage of bevacizumab injection is 7.5 mg / kg, administered by intravenous infusion, once on the first day every 3 weeks, and every 3 weeks is a treatment cycle;
[0113] Oxaliplatin injection: The dosage is 130 mg / m 2 , intravenous infusion, once on the first day every 3 weeks, one treatment cycle every 3 weeks; up to 8 treatment cycles;
[0114] Capecitabine tablets: Dosage: 1000 mg / m 2 , orally, twice a day, start taking the medicine on the first day every 3 weeks, stop taking the medicine for 1 week after taking the medicine for 2 weeks, and every 3 weeks is a treatment cycle; the longest medication period is 2 years.
[0115] Interim effectiveness results:
[0116] This study is still enrolling. As of March 13, 2023, Cohort 1 has enrolled 3 subjects, all of whom have had at least one post-treatment tumor assessment. Two of these subjects achieved a PR, and one achieved SD, with an ORR of 66.7% and a DCR of 100%. Cohort 2 has enrolled 14 subjects, 8 of whom have had at least one post-treatment tumor assessment. Four of these subjects achieved a PR, and four achieved SD, with an ORR of 50% and a DCR of 100%. Among the four subjects with a best response of SD, three had only their first tumor assessment, and one had two tumor assessments. The tumor reduction percentages were 23%, 26%, 29%, and 29%, respectively, very close to the PR criteria (minimum 30% reduction). Continued study treatment is expected to result in a high probability of achieving a PR.
[0117] Conclusions: ZPML265 monotherapy for MSI-H CRC, or ZPML265 combined with bevacizumab and chemotherapy, has demonstrated outstanding efficacy data.
[0118] Safety results:
[0119] As of March 13, 2023, among the three subjects in Cohort 1, one (33.3%) experienced a TEAE, and no adverse events related to ZPML265 had occurred. In Cohort 2, 11 subjects entered the safety analysis set, and 7 (63.6%) experienced TEAEs, all of which were AEs related to the combination drug (TRAEs). The main TRAEs (occurring in ≥2 subjects) were decreased neutrophil count (3, 27.3%), decreased platelet count (3, 27.3%), decreased white blood cell count (2, 18.2%), vomiting (2, 18.2%), nausea (2, 18.2%), and diarrhea (2, 18.2%). One (9.1%) subject experienced a TRAE of grade ≥ 3, which were decreased platelet count (9.1%) and hypertriglyceridemia (9.1%). One (9.1%) subject experienced a SAE, which was decreased platelet count (9.1%). No TEAEs leading to death occurred.
[0120] Safety data suggest that ZPML265 has good safety when used alone; when combined with bevacizumab and chemotherapy, the main manifestations are chemotherapy-related hematological toxicity and gastrointestinal reactions, which are well tolerated.
[0121] in conclusion:
[0122] In summary, ZPML265 monotherapy demonstrated preliminary efficacy superior to PD-(L)1 monotherapy in first-line treatment of patients with MSI-H advanced CRC, with a favorable safety profile and no new safety signals. ZPML265 combined with bevacizumab and chemotherapy demonstrated preliminary efficacy in first-line treatment of patients with MSS advanced CRC, with tumor size reduction trends observed in all subjects, and the combination therapy did not increase safety risks.
Claims
1. A pharmaceutical composition for treating colorectal cancer, comprising an effective amount of a mixed antibody of anti-CTLA4 and anti-PD1, wherein the mixed antibody is produced by a single host cell containing nucleic acids encoding two different antibodies, anti-CTLA4 and anti-PD1, wherein: The sequences of the anti-CTLA4 antibody heavy chain HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 1, 2 and 3, respectively; the sequences of the anti-CTLA4 antibody light chain LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 4, 5 and 6, respectively; the sequences of the anti-PD1 antibody heavy chain HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 9, 10 and 11, respectively; and the sequences of the anti-PD1 antibody light chain LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 12, 13 and 14, respectively.
2. The pharmaceutical composition according to claim 1, wherein The heavy chain variable region sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 7, the light chain variable region sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 8, the heavy chain variable region sequence of the anti-PD1 antibody is shown in SEQ ID NO: 15, and the light chain variable region sequence of the anti-PD1 antibody is shown in SEQ ID NO:
16.
3. The pharmaceutical composition according to claim 1, wherein The heavy chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 17, the light chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 18, the heavy chain sequence of the anti-PD1 antibody is shown in SEQ ID NO: 19, and the light chain sequence of the anti-PD1 antibody is shown in SEQ ID NO:
20.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the colorectal cancer is unresectable or metastatic colorectal cancer.
5. The pharmaceutical composition of claim 4, wherein the unresectable or metastatic colorectal cancer is mismatch repair protein-deficient (dMMR) or high microsatellite instability (MSI-H) colorectal cancer.
6. The pharmaceutical composition according to claim 5, wherein the dosage of the mixed antibody is 5 mg / kg, administered once every three weeks by intravenous infusion on the first day, and a treatment cycle of 21 days.
7. The pharmaceutical composition according to claim 4, wherein the unresectable or metastatic colorectal cancer is microsatellite stable (MSS) colorectal cancer.
8. The pharmaceutical composition according to claim 7, wherein the KRAS, NRAS and BRAF genes of the microsatellite stable (MSS) colorectal cancer are all wild-type.
9. The pharmaceutical composition according to claim 7, wherein any one of the KRAS, NRAS and BRAF genes of the microsatellite stable (MSS) colorectal cancer is a mutant type.
10. The pharmaceutical composition according to any one of claims 7 to 9, wherein the dosage of the mixed antibody is 5 mg / kg, administered once every three weeks by intravenous infusion on day 1, and a treatment cycle of 21 days.
11. The pharmaceutical composition according to any one of claims 7 to 9, further comprising a chemotherapeutic drug and an anti-angiogenic agent.
12. The pharmaceutical composition according to claim 11, wherein the chemotherapy drugs are oxaliplatin and capecitabine, and the anti-angiogenic agent is bevacizumab.
13. The pharmaceutical composition according to claim 12, wherein the dosage of oxaliplatin is 130 mg / m 2 , administered by intravenous infusion on the first day, with a treatment cycle of 21 days; the dose of capecitabine was 1000 mg / m 2 , orally, twice a day, starting on the first day of every 3 weeks, stopping for 1 week after every 2 weeks of medication, and every 3 weeks as a treatment cycle; the dosage of bevacizumab is 7.5 mg / kg, administered by intravenous infusion on the first day, and 21 days as a treatment cycle.
14. A method for treating colorectal cancer, comprising administering to a subject a pharmaceutical composition comprising an effective amount of a mixed antibody comprising anti-CTLA4 and anti-PD1, wherein the mixed antibody is produced by a single host cell containing nucleic acids encoding two different antibodies, anti-CTLA4 and anti-PD1, wherein: The sequences of the anti-CTLA4 antibody heavy chain HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 1, 2 and 3, respectively; the sequences of the anti-CTLA4 antibody light chain LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 4, 5 and 6, respectively; the sequences of the anti-PD1 antibody heavy chain HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 9, 10 and 11, respectively; and the sequences of the anti-PD1 antibody light chain LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 12, 13 and 14, respectively.
15. The method of claim 14, wherein: The heavy chain variable region sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 7, the light chain variable region sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 8, the heavy chain variable region sequence of the anti-PD1 antibody is shown in SEQ ID NO: 15, and the light chain variable region sequence of the anti-PD1 antibody is shown in SEQ ID NO:
16.
16. The method of claim 14, wherein: The heavy chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 17, the light chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 18, the heavy chain sequence of the anti-PD1 antibody is shown in SEQ ID NO: 19, and the light chain sequence of the anti-PD1 antibody is shown in SEQ ID NO:
20.
17. The method according to any one of claims 14 to 16, wherein the colorectal cancer is unresectable or metastatic colorectal cancer.
18. The method of claim 17, wherein the unresectable or metastatic colorectal cancer is mismatch repair protein-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer.
19. The method according to claim 18, wherein the dosage of the mixed antibody is 5 mg / kg, administered once every three weeks by intravenous infusion on day 1, and a treatment cycle of 21 days.
20. The method of claim 17, wherein the unresectable or metastatic colorectal cancer is microsatellite stable (MSS) colorectal cancer.
21. The method of claim 20, wherein the KRAS, NRAS and BRAF genes of the microsatellite stable (MSS) colorectal cancer are all wild-type.
22. The method of claim 20, wherein any one of KRAS, NRAS and BRAF genes in the microsatellite stable (MSS) colorectal cancer is mutated.
23. The method according to any one of claims 20 to 22, wherein the dosage of the mixed antibody is 5 mg / kg, administered once every three weeks by intravenous infusion on day 1, and a treatment cycle of 21 days.
24. The method of any one of claims 20-22, further comprising a chemotherapeutic drug and an anti-angiogenic agent.
25. The method of claim 24, wherein the chemotherapy drugs are oxaliplatin and capecitabine, and the anti-angiogenic agent is bevacizumab.
26. The method of claim 25, wherein the dosage of oxaliplatin is 130 mg / m 2 , administered by intravenous infusion on day 1, with a treatment cycle of 21 days; the dose of capecitabine was 1000 mg / m 2 , orally, twice a day, starting on the first day of every 3 weeks, stopping for 1 week after every 2 weeks of medication, and every 3 weeks as a treatment cycle; the dosage of bevacizumab is 7.5 mg / kg, administered by intravenous infusion on the first day, and 21 days as a treatment cycle.
27. A pharmaceutical composition for treating unresectable or metastatic colorectal cancer, comprising an effective amount of a mixed antibody of anti-CTLA4 and anti-PD1, wherein the mixed antibody is produced by a single host cell containing nucleic acids encoding two different antibodies, anti-CTLA4 and anti-PD1, wherein: The heavy chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 17, the light chain sequence of the anti-CTLA4 antibody is shown in SEQ ID NO: 18, the heavy chain sequence of the anti-PD1 antibody is shown in SEQ ID NO: 19, and the light chain sequence of the anti-PD1 antibody is shown in SEQ ID NO: 20.
